We would like to submit the following correction to our recently published paper \[[@B1-nutrients-09-00641]\] because the wrong dose of probiotic was reported. The probiotic dosage has been corrected throughout [Table 1](#nutrients-09-00641-t001){ref-type="table"} and [Table 2](#nutrients-09-00641-t002){ref-type="table"} ([Table 1](#nutrients-09-00641-t001){ref-type="table"}: in the fifth column of the sixth row and in the fifth column of the seventh row, 2 × 10^10^ was changed to 1 × 10^10^; [Table 2](#nutrients-09-00641-t002){ref-type="table"}: in the fourth column of the seventeenth row, 2 × 10^10^ was changed to 1 × 10^10^). The correct tables are shown below.

These corrections induced a few minor changes in the text of the results section. As a consequence of this correction, the following sentences should be corrected:

Results
=======

On page 9, the second sentence of paragraph three, of the original publication \[[@B1-nutrients-09-00641]\] incorrectly stated "However, the dosage tested in the study (20 billion colony forming units (cfu) per day) was twenty times the dosage found in the product (1 billion cfu per day).". Instead, this statement should read "However, the dosage tested in the study (10 billion colony forming units (cfu) per day) was ten times the dosage found in the product (1 billion cfu per day).".

These changes have no material impact on the conclusions of our paper. The manuscript will be updated and the original will remain online on the article webpage. We apologize for any inconvenience caused to our readers.

nutrients-09-00641-t001_Table 1

###### 

Strains in probiotic food products and reported health effects associated with these strains.

  Strain(s)                                                           Manufacturer and Product Brand                 Food Type          Probiotic Dosage in Food (CFU \*/Serving)   Dosage Tested in Studies (CFU \*/Day)   Duration of Study    Health Effects Investigated in Healthy Populations                                                                                                                                                                                     
  ------------------------------------------------------------------- ---------------------------------------------- ------------------ ------------------------------------------- --------------------------------------- -------------------- ---------------------------------------------------- --------------- --------------- -------------------------------- ---------- --------------- ----------------------------------- --------------- --------------- ----------------- -------------------
  *Bifidobacterium lactis* BB12 + *Lactobacillus acidophilus* LA-5    Yoplait's *Yoptimal*, Lucerne's *Organics* †   Yogurt             \>1 × 10^9^                                 2 × 10^6^--3 × 10^9^                    7 days--6 weeks                                                           X \[20\] ^\$^                                                    O \[21\]   O \[20\] ^\$^                                                                       **O** \[22,23\]   **x** \[24,25\]
  *Bifidobacterium lactis* BB12                                       Iogo's *Probio \*\**, Yoplait's *Minigo*       Yogurt             \>1 × 10^9^                                 1 × 10^10^--3.5 × 10^10^                10 days---3 months                                                                                                                                                    o \[26\] ^\$^ \[27\]                                O \[28\] ^\$^                     **X** \[29\]
  *Lactobacillus casei* DN 114-001                                    Danone's *DanActive*                           Drinkable yogurt   1 × 10^10^                                  1 × 10^10^--3 × 10^10^                  2 weeks --6 months   x \[30\] ^\$^, \[31\] o \[32\] ^\$^                  X \[33\] ^\$^                                                               x \[34\] ^\$^   X \[35,36\] ^\$^ x \[26,30\] ^\$^   x \[37\] ^\$^                                     
  *Bifidobacterium lactis* DN-173 010                                 Danone's *Activia*                             Yogurt             \>1 × 10^9^                                 8 × 10^9^--2.5 × 10^10^                 2--4 weeks                                                                                o \[38\] ^\$^   X \[39,40\] ^\$^ x \[38\] ^\$^                                                                                                                    **O** \[41\] ^\$^
  *Lactobacillus acidophilus* NCFM + *Bifidobacterium lactis* Bi-07   Astro's *BioBest*                              Yogurt             1 × 10^9^                                   1 × 10^10^                              6 months             o \[42\] ^\$^                                                                                                                                    x \[42\] ^\$^                                                                         
  *Lactobacillus acidophilus* NCFM                                    President's Choice's *ProAdvantage†*           Yogurt             1 × 10^9^                                   1 × 10^10^                              6 months             o \[42\] ^\$^                                                                                                                                    x \[42\] ^\$^                                                                         

X = beneficial effects observed in healthy adults; x = beneficial effects observed in healthy children, O = studies that have investigated this outcome and have found no significant effect in adults, o = studies that have investigated this outcome and found no significant effect in children, ^\$^ = indicates that the research was funded by the company that uses that particular strain in their products. A blank square indicates that no research investigating the effects of that strain/strain combination was identified during the systematic review of all literature published up to 21 July 2016, as described in the methods. All effects reported in this table were found in healthy populations that were not diagnosed with a chronic disease or condition. Definition of health effects: Constipation = improved stool frequency, consistency, or condition; Acute diarrhea = decreased incidence or severity of acute diarrhea; Antibiotic-associated diarrhea = decreased incidence of antibiotic-associated or *Clostridium difficile*-associated diarrhea; Digestive symptoms = decreased abdominal pain/discomfort, bloating, flatulence, or overall GI well-being; Glycemic control = improved fasting glucose, insulin, HbA1c (marker of long-term glycemic control), or HOMA-IR (measure of insulin sensitivity); *Helicobacter pylori* eradication = enhanced eradication of *Helicobacter pylori* infections; Immunity = decreased incidence and/or duration of common infectious diseases, including fever, cough, common respiratory infections (rhinitis, sore throat), common gastrointestinal infections (gastroenteritis, vomiting), asthma, or days missed from school; Infant breastfeeding outcomes = infants (2--6 months old) of mothers who consume this strain while breastfeeding had decreased incidence of gastrointestinal episodes and lower medication-use rates; Inflammation = decreased levels of inflammatory markers (ex. C-reactive protein); Lipids = decreased serum total cholesterol, low density lipoprotein (LDL), triglyceride levels, or increased high density lipoprotein (HDL); Oral health = decreased levels of cavity causing bacteria. \* CFU = colony forming units. \*\* Iogo's *Probio* reported two strains on its label in 2013 (*Bifidobacterium lactis* BB12 + *Lactobacillus acidophilus* LA-5) and only one strain on its label in 2016. † These products were available in 2013 but may no longer be available in the Canadian market. Note: All cited references were deemed to be of high quality according to Health Canada's quality appraisal tool for intervention studies \[18\].

nutrients-09-00641-t002_Table 2

###### 

Results of the review of randomized controlled trials investigating the health effects of probiotic strains found in the Canadian food supply ^1^.

  Strain                                                Study, Country (Year)                                 Population (*n*)                         Probiotic Dosage (CFU per day)   Study Duration                                                                                                                                                                                                                                                                                                                                             Outcome Measures (Primary and Secondary)                                                                                                                                                                                                                                                                                                                                          Statistically Significant Effects (Relative to Placebo Group)                                                                      Funding Source
  ----------------------------------------------------- ----------------------------------------------------- ---------------------------------------- -------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- -------------------------------
  *B lactis* BB12 + *L acidophilus* LA-5                Ivey et al. \[21\] Australia (2014)                   Overweight adults *n* = 156              3 × 10^9^                        6 weeks                                                                                                                                                                                                                                                                                                                                                    **Primary:** Glycemic control (fasting blood glucose, insulin, HbA1c, and HOMA-IR)                                                                                                                                                                                                                                                                                                Increased HOMA-IR (worsened insulin sensitivity)                                                                                   Sir Charles Gairdner Hospital
  Sadrzadeh-Yeganeh et al. \[23\] Iran (2010)           Females *n* = 90                                      3.9 × 10^7^                              6 weeks                          **Primary:** Serum total cholesterol, HDL, LDL, and triglycerides                                                                                                                                                                                                                                                                                          No observed effects                                                                                                                                                                                                                                                                                                                                                               Tehran University Grant                                                                                                            
  Ivey et al. \[22\] Australia (2015)                   Overweight adults *n* = 156                           3 × 10^9^                                6 weeks                          **Primary:** Blood pressure, total cholesterol, HDL, LDL, and triglycerides                                                                                                                                                                                                                                                                                No observed effects                                                                                                                                                                                                                                                                                                                                                               Sir Charles Gairdner Hospital                                                                                                      
  deVrese et al. \[20\] Germany (2011)                  H pylori infected adults *n* = 88                     5 × 10^6^                                5 weeks                          **Primary:** *Helicobacter pylori* activity; **Secondary:** Frequency, intensity and duration of abdominal pain; stool frequency/consistency; duration of diarrhea episodes; IBS symptoms; orofecal transit time                                                                                                                                           Decreased duration of antibiotic-associated diarrhea episodes                                                                                                                                                                                                                                                                                                                     Chr. Hansen GmbH J. & Co., KG, NOM AG ^\$^                                                                                         
  Ashwin et al. \[24\] India (2015)                     Children *n* = 60                                     2 × 10^6^                                7 days                           **Primary:** Salivary levels of streptococcus mutans (a cavity causing bacteria)                                                                                                                                                                                                                                                                           Reduced salivary *mutans streptococci*                                                                                                                                                                                                                                                                                                                                            Funded by study author                                                                                                             
  Singh et al. \[25\] India (2011)                      Children *n* = 40                                     5.4 × 10^7^                              10 days                          **Primary:** Salivary levels of salivary *mutans streptococci* and *lactobacilli* (cavity causing bacteria)                                                                                                                                                                                                                                                Reduced salivary *mutans streptococci*                                                                                                                                                                                                                                                                                                                                            Not disclosed                                                                                                                      
  Ejtahed et al. \[43\] Iran (2011)                     Type II Diabetics *n* = 64                            \>1 × 10^9^                              6 weeks                          **Primary:** Fasting blood glucose, HbA1c, insulin and antioxidant molecules (superoxide dismutase, glutathion peroxidase, catalase activity, malondialdehyde concentration, and total antioxidative status)                                                                                                                                               Decreased fasting blood glucose and HbA1c; increased activity of superoxide dismutase, glutathoine peroxidase, and total antioxidative status                                                                                                                                                                                                                                     Iran Dairy Industry ^\$^                                                                                                           
  Mohamadshahi et al. \[44\] Iran (2014)                Type II Diabetics *n* = 44                            \>1 × 10^9^                              8 weeks                          **Primary:** Serum triglycerides, LDL, HDL, triglycerides, LDL:HDL                                                                                                                                                                                                                                                                                         Decreased LDL:HDL, increased HDL                                                                                                                                                                                                                                                                                                                                                  Nutrition Disease Research Center                                                                                                  
  Ejtahed et al.\[45\] Iran (2012)                      Type II Diabetics *n* = 60                            6 × 10^8^                                6 weeks                          **Primary:** total cholesterol, triglycerides, HDL, LDL, total cholesterol:HDL, LDL:HDL                                                                                                                                                                                                                                                                    Decreased total cholesterol, LDL, LDL:HDL and total cholesterol:HDL                                                                                                                                                                                                                                                                                                               Grant from Tabriz University                                                                                                       
  Nabavi et al. \[46\] Iran (2014)                      Non-alcoholic fatty liver disease patients *n* = 72   \>1 × 10^9^                              8 weeks                          **Primary:** Blood levels of liver enzymes (alanine aminotransferase and aspartate aminotransferase); fasting blood glucose; total cholesterol, triglycerides, LDL, HDL.                                                                                                                                                                                   Decreased blood levels of liver enzymes, total cholesterol, triglycerides, and LDL                                                                                                                                                                                                                                                                                                Nutrition Research Center, Tabriz University                                                                                       
  Tonucci et al. \[47\] Brazil (2015)                   Type II Diabetics *n* = 45                            2 × 10^9^                                6 weeks                          **Primary:** Glycemic control (fasting blood glucose, insulin, HOMA-IR, fructosamine, HbA1c); lipid profile (total cholesterol, LDL, VLDL, triglycerides, total cholesterol:HDL); total antioxidant status and cytokine concentrations (Il-6, Il-10, TNF-α, adiponectin, and resistin); fecal short-chain fatty acids                                      Decreased fructosamine, LDL, and total cholesterol; significant change in HbA1c                                                                                                                                                                                                                                                                                                   Brazilian Agri-Research; Foundation to Support the State of Miras Gerais                                                           
  *B. lactis* BB12                                      Caglar et al. \[29\] Turkey (2008)                    Healthy young adults *n* = 24            5 × 10^8^                        10 days                                                                                                                                                                                                                                                                                                                                                    **Primary:** Salivary levels of *mutans streptococci* and *lactobacilli* (cavity causing bacteria)                                                                                                                                                                                                                                                                                Decreased salivary *mutans streptococi*                                                                                            Funded by researchers
  Merenstein et al. \[48\] USA (2010)                   Children *n* = 182                                    1 × 10^10^                               90 days                          **Primary:** Missed days of school due to illness; **Secondary:** Diarrhea, stool consistency, respiratory infection, missed parental work, doctor visits, illnesses, and overall parental satisfaction                                                                                                                                                    No observed effects                                                                                                                                                                                                                                                                                                                                                               The Gerber Foundation ^\$^                                                                                                         
  Merenstein et al. \[27\] USA (2011)                   Healthy children *n* = 172                            1 × 10^10^                               90 days                          **Primary:** Missed days of school due to illness; **Secondary:** Diarrhea, stool consistency, respiratory infection, missed parental work, doctor visits, illnesses                                                                                                                                                                                       No observed effects                                                                                                                                                                                                                                                                                                                                                               USDA                                                                                                                               
  Kekkonen et al. \[28\] Finland (2008)                 Healthy adults *n* = 62                               3.5 × 10^10^                             3 weeks                          **Primary:** Blood levels of inflammatory markers including C-reactive protein and cytokines (TNF-α, IL-6, IFN-γ, IL-10)                                                                                                                                                                                                                                   No observed effects                                                                                                                                                                                                                                                                                                                                                               Resaerch Council Finland and Valio ^\$^                                                                                            
  *L. acidophilus* NCFM + *B. lactis* Bi-07             Leyer et al. \[42\] China (2009)                      Healthy children *n* = 326               1 × 10^10^                       6 months                                                                                                                                                                                                                                                                                                                                                   **Primary:** Frequency and duration of fever, cough, rhinorrhea, vomiting, diarrhea, physicians\' visits and antibiotic prescriptions; **Secondary:** School absences                                                                                                                                                                                                             Decreased incidence of fever, cough, rhinorrhea, antibiotic use, and days missed from school. Reduced symptom duration.            Danisco ^\$^
  *B. lactis* DN-173 010                                Pinto et al.\[41\] Brazil (2013)                      Healthy adults *n* = 26                  not reported                     2 weeks                                                                                                                                                                                                                                                                                                                                                    **Primary:** Salivary levels of cavity-associated microorganisms (*mutans streptococci*, *lactobacilli* and total microorganisms) in saliva                                                                                                                                                                                                                                       No observed effects                                                                                                                Not Disclosed
  Tabbers et al. \[38\] Netherlands and Poland (2011)   Constipated children *n* = 159                        \>8 × 10^9^                              3 weeks                          **Primary:** Stool frequency; **Secondary:** Stool consistency, frequency of faecal incontinence, pain during defecation, abdominal pain, flatulence                                                                                                                                                                                                       Decreased flatulence                                                                                                                                                                                                                                                                                                                                                              Danone ^\$^                                                                                                                        
  Guyonnet et al. \[39\] Germany (2009)                 Healthy adult women *n* = 192                         2.5 × 10^10^                             4 weeks                          **Primary:** Overall GI well-being (intestinal transit, stool frequency and consistency, abdominal pain/discomfort, bloating, flatulence, stomach rumbling); **Secondary:** Frequency of digestive symptoms including abdominal pain/discomfort, bloating, flatulence, stomach rumbling; stool frequency and consistency; health-related quality of life   Improved overall GI well-being; decreased frequency of flatulence, stomach rumbling, improved stool consistency, and health-related quality of life.                                                                                                                                                                                                                              Danone ^\$^                                                                                                                        
  Agrawal et al. \[40\] United Kingdom (2008)           Adult females with IBS *n* = 34                       2.5 × 10^10^                             4 weeks                          **Primary:** Abdominal distension and bloating; **Secondary:** Orocaecal and colonic transit times; incidence and severity of IBS symptoms (abdominal pain/discomfort, bloating, flatulence); overall IBS symptom severity; time and consistency of bowel movements; feelings of incomplete evacuation at time of stool passage                            Decreased maximal abdominal distension, orocaecal and colonic transit times, overall IBS symptom severity, and abdominal pain/discomfort.                                                                                                                                                                                                                                         Danone ^\$^                                                                                                                        
  *L. casei* DN 114-001                                 Guillemard et al. \[35\] Germany (2010)               Healthy adult shift workers *n* = 1000   \>2 × 10^10^                     3 months                                                                                                                                                                                                                                                                                                                                                   **Primary:** Cumulative number of common infectious diseases (CID) (e.g., sore throat, sinusitus, nasal discharge, ear ache, influenza, pneumonia, cough, GI infection, diarrhea, nausea vomiting) **Secondary:** Occurrence of having at least one CID: time to first CID, severity, duration, cumulated duration; occurrence and duration of fever, sick days, medication use   Decreased occurrence and time to first CID; decreased duration of fever; decreased cumulative number of CIDs (post-hoc analysis)   Danone ^\$^
  Merenstein et al. \[26\] USA (2010)                   Healthy children *n* = 638                            \>2 × 10^10^                             3 months                         **Primary:** Change in behaviour due to illness (e.g., missed school, missed sports activity); incidence of common infectious diseases (CIDs) **Secondary:** Absences from daycare or school, missed parental work, days with diarrhea, vomiting, stomach pain, constipation, runny nose, cough, decreasing appetite, fever, rash, medication use          Decreased incidence of CID                                                                                                                                                                                                                                                                                                                                                        Danone ^\$^                                                                                                                        
  Guillemard et al. \[36\] France (2009)                Elderly adults *n* = 1072                             \>2 × 10^10^                             3 months                         **Primary:** Cumulative number of all common infectious diseases (CID) **Secondary:** The occurrence of CID (defined as the number of subjects experiencing at least one CID), duration of CID (cumulative and per episode), time to first CID, severity of CID, fever associated with CID, occurrence or duration of medication use                       Decreased duration of CID episodes and cumulative duration of CID                                                                                                                                                                                                                                                                                                                 Danone ^\$^                                                                                                                        
  Sykora et al. \[34\] Czech Republic (2005)            Children w/H Pylori *n* = 86                          1 × 10^10^                               14 days                          **Primary:** Eradication rate of *Helicobacter pylori* infection                                                                                                                                                                                                                                                                                           Increased *Helicobacter pylori* eradication rates                                                                                                                                                                                                                                                                                                                                 Ministry of Health and Danone ^\$^                                                                                                 
  Ortiz-Andrellucchi et al. \[37\] Spain (2008)         Breastfeeding infants *n* = 104                       3 × 10^10^                               6 weeks                          **Primary:** Immunomodulatory molecules in breast milk (not included in this review) **Secondary:** Infant growth and weight; incidence of gastrointestinal episodes, respiratory symptoms, medication use, allergies and dermatitis                                                                                                                       Reduced incidence of gastrointestinal episodes and lower rate of medication use in infants                                                                                                                                                                                                                                                                                        Danone ^\$^                                                                                                                        
  Agarwal et al. \[31\] India (2002)                    Children *n* = 150                                    2--3 × 10^10^                            9 months                         **Primary:** Duration of acute diarrhea                                                                                                                                                                                                                                                                                                                    Decreased duration of acute diarrhea                                                                                                                                                                                                                                                                                                                                              Not Disclosed                                                                                                                      
  Hickson et al. \[33\] United Kingdom (2007)           Elderly in-patients *n* = 137                         2 × 10^10^                               2 weeks                          **Primary:** Incidence of antibiotic-associated diarrhea and *Clostridium difficile* associated diarrhea                                                                                                                                                                                                                                                   Decreased incidence of antibiotic- and *Clostridium*-associated diarrhea                                                                                                                                                                                                                                                                                                          Danone ^\$^                                                                                                                        
  Giovannini et al. \[30\] Italy (2007)                 Children with asthma/rhinitis *n* = 187               1 × 10^10^                               12 months                        **Primary:** Episodes and duration of asthma and rhinitis (runny/stuff nose) **Secondary:** Episodes and duration of abdominal symtoms, diarrhea and fever                                                                                                                                                                                                 Decreased asthma and rhinitis episodes, decreased duration of diarrhea in children with rhinitis                                                                                                                                                                                                                                                                                  Danone ^\$^                                                                                                                        
  Giralt et al. \[49\] Spain (2008)                     Gynecological cancer patients *n* = 85                2.8 × 10^10^                             6 months                         **Primary:** Frequency and severity of radiation induced diarrhea **Secondary:** Time to the development of diarrhea, stool consistency                                                                                                                                                                                                                    Improved stool consistency                                                                                                                                                                                                                                                                                                                                                        Danone ^\$^                                                                                                                        

^1^ All probiotic strains in the Canadian food supply were recorded and a systematic review of their health effects was conducted. All literature published up to 21 July 2016 was included, as described in the methods. All studies included in the review were deemed to be of a "high quality" according to Health Canada's quality appraisal tool for intervention studies and thus are considered eligible to substantiate a health claim \[18\]. ^\$^ Indicates that funding was provided by the food industry HbA1c = hemoglobin A1c, a long-term measure of glycemic control; HOMA-IR = a measure of insulin sensitivity; LDL = low-density lipoprotein; HDL = high-density lipoprotein; VLDL = very low-density lipoprotein; IBS = irritable bowel syndrome; CID = common infectious diseases.
